SCYNEXIS Signs Deal with R-Pharm
News Sep 12, 2013
SCYNEXIS, Inc. and R-Pharm have announced that they have entered into an agreement granting R-Pharm exclusive rights to develop and commercialize SCY-078 in Russia and several other markets.
SCYNEXIS retains the rights to market the compound in The Americas, Europe and Asia. SCY-078 is an oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases such as candidemia and aspergillosis.
“Glucan synthase inhibitors have been very effective in treating invasive fungal infections in a hospital setting, but are currently only available as an intravenous dosing option,” said Alexey Repik, president and chairman, R-Pharm.
Repik continued, “As the first oral glucan synthase inhibitor, SCY-078 could prove very useful in markets where intravenous dosing options have resulted in under treatment or treatment limitations.”
“This partnership with R-Pharm is an important milestone in the advancement of SCY-078 toward Phase 2 clinical development and beyond,” said Yves Ribeill, Ph.D., president and chief executive officer, SCYNEXIS. “We welcome R-Pharm’s contributions to the development and commercialization of SCY-078, which provides us access to some very important and potentially large markets, including Russia.”
Under the terms of this agreement, R-Pharm will develop and register SCY-078 in its territories including Russia, The Commonwealth of Independent States and Turkey.
SCYNEXIS receives an upfront payment and is entitled to receive payments on development and commercialization milestones and royalties. Further details of the agreement are not disclosed.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018